Latest Articles

Our knowledge of how pathological proteins like amyloid spread and become deposited throughout the brain in many major neurodegenerative diseases is now extensive. Nevertheless, our improved understanding of Alzheimer’s molecular mechanisms has yet to bridge over to effective treatments that reverse disease progress. Are we any closer to a cure?

Pressurized metered dose inhalers are the dominant form of treatment for millions of asthma sufferers. But, with the need to phase out high global warming potential propellants that are currently integral to device function, what does the future look like for pMDI use?

This article will discuss how cell models are enabling researchers to elucidate the underlying biological mechanisms of disease to support diagnostic and therapeutic development.

This article discusses how marrying microfluidics with automation can provide the necessary level of control to perform high‑throughput LNP formulation screening in a cost-effective and timely manner, and how this approach can accelerate the development of new nanomedicines.

Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.

In May, news broke of the first UK baby to be born through a new type of IVF procedure, called mitochondrial replacement therapy (MRT). We speak to a mitochondria expert to learn more about the procedure and why it is ethically "controversial".

Scientists have discovered an alternative, novel source of the important anticoagulant heparin, extracted from the mucus of the giant African snail.

This article explores the various screening technologies used in the development of therapeutic antibodies and outlines the recent advances in this area.

Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.

Technology Networks had the pleasure of speaking with Walid A. Houry, professor of biochemistry at the University of Toronto, to find out about the discovery of compounds that can induce protease hyperactivation to kill cancer cells.